Role of Gut Microbiota in Diabetic HFpEF: Mechanisms and Therapeutic Implications
Diabetes, Metabolic Syndrome and Obesity · 2026-08 · Volume 19 · 1-20
DOI: 10.2147/dmso.s613343 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Metabolic Syndrome and Obesity, 2026-08. Verfasst von Hongyan Fan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, 314000, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Heart failure with preserved ejection fraction (HFpEF) is rapidly emerging as a predominant form of heart failure worldwide. Its pathogenesis extends beyond traditional hemodynamic abnormalities and involves multiple pathways, such as systemic metabolism, inflammation, and endothelial dysfunction. Type 2 diabetes mellitus (T2DM), which is present in up to 45% of patients with HFpEF, is one of the most common and clinically important comorbidities of HFpEF. T2DM not only significantly increases its incidence but also leads to more severe complications and poorer prognosis, constituting a distinct clinical phenotype known as "diabetic HFpEF." In recent years, the role of the gut microbiota (GMB) as a central hub linking metabolism and the cardiovascular system has become increasingly prominent. This review summarizes the epidemiological and pathophysiological connections between T2DM and HFpEF, with a focus on characteristic alterations in gut dysbiosis in patients with diabetic HFpEF and the underlying mechanisms involving microbiota-derived metabolites, including short-chain fatty acids (SCFAs), trimethylamine N-oxide (TMAO), and bile acids (BAs). It also discusses how the cardiovascular protective effects of novel antidiabetic drugs are closely related to their potential mechanisms of modulating gut microbiota ecology and restoring metabolic balance. However, current evidence remains largely mechanistic and observational, and the causal relationships between gut dysbiosis and diabetic HFpEF require further validation. Overall, GMB represents an important and modifiable target in patients with diabetic HFpEF, offering new directions for both mechanistic research and therapeutic interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, The Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, 314000, People's Republic of China.
- Department of Endocrinology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, 314000, People's Republic of China.
ORCID-Profile: Hongyan Fan, Junli Wu, Yufen Shen, Wenwen Zheng
Zitieren
APA
Fan, H., Wu, J., Shen, Y., & Zheng, W. (2026). Role of Gut Microbiota in Diabetic HFpEF: Mechanisms and Therapeutic Implications. Diabetes, Metabolic Syndrome and Obesity, Volume 19, 1-20. https://doi.org/10.2147/dmso.s613343
Vancouver
Fan H, Wu J, Shen Y, Zheng W. Role of Gut Microbiota in Diabetic HFpEF: Mechanisms and Therapeutic Implications. Diabetes, Metabolic Syndrome and Obesity. 2026;Volume 19:1-20. doi:10.2147/dmso.s613343
BibTeX
@article{Fan2026,
author = {Fan, Hongyan and Wu, Junli and Shen, Yufen and Zheng, Wenwen},
title = {Role of Gut Microbiota in Diabetic HFpEF: Mechanisms and Therapeutic Implications},
journal = {Diabetes, Metabolic Syndrome and Obesity},
year = {2026},
volume = {Volume 19},
pages = {1--20},
doi = {10.2147/dmso.s613343}
}
EUVIMED